Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Wellspring Ophthalmics’ newly acquired proprietary broad formulation platform is an innovative suspension comprising aqueous, amorphous nanodispersions of cyclosporine. These formulations are designed to have higher bioavailability for better efficacy and improved dry eye.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: Newport Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2022